Protection effects of Astragaloside on heart

A technology of astragaloside IV and myocardium is applied in the field of the protective effect of astragaloside IV on the heart, and can solve the problems of lack of cardiac contractility, abnormal myocardial structure and function, etc.

Inactive Publication Date: 2014-11-19
TIANJIN TASLY PHARMA CO LTD
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Thus, ATP deficiency is an important factor in the decreased contractile capacity of the heart, since ATP deficiency leads to F‐actin degradation and phosphorylation of myosin light chains, which in turn lead to structural and functional abnormalities of the myocardium

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protection effects of Astragaloside on heart
  • Protection effects of Astragaloside on heart
  • Protection effects of Astragaloside on heart

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0131] tablet

[0132] 【prescription】

[0133] Astragaloside IV 100g

[0134] Microcrystalline cellulose 50g

[0135] Micropowder silica gel 3g

[0136] Magnesium stearate 1.5g

[0137] [Preparation method] Take raw materials and auxiliary materials and pass through 100-mesh sieve respectively; take astragaloside IV and microcrystalline cellulose, mix well, use 60% ethanol as a binder to make soft material, pass through 20-mesh sieve to make granules, and dry at 60°C , take it out, sieve through a 30-mesh sieve for granulation, add micropowder silica gel and magnesium stearate, mix well, press into tablets, and make 1,000 tablets, to obtain.

Embodiment 2

[0139] 【prescription】

[0140] Astragaloside IV 75g

[0141] Microcrystalline cellulose 37g

[0142] Micropowder silica gel 2.3g

[0143] Magnesium stearate 1.1g

[0144] [Preparation method] Take raw materials and auxiliary materials and pass through 100-mesh sieve respectively; take astragaloside IV and microcrystalline cellulose, mix well, use 60% ethanol as a binder to make soft material, pass through 20-mesh sieve to make granules, and dry at 60°C , take it out, sieve through a 30-mesh sieve for granulation, add appropriate amount of micropowder silica gel and magnesium stearate, mix well, press into tablets, and make 1000 pieces, to obtain.

Embodiment 3

[0146] 【prescription】

[0147] Astragaloside IV B133g

[0148] Microcrystalline cellulose 66g

[0149] Micropowder silica gel 4g

[0150] Magnesium stearate 2g

[0151] [Preparation method] Take raw materials and auxiliary materials and pass through 100-mesh sieve respectively; take astragaloside IV and microcrystalline cellulose, mix well, use 60% ethanol as a binder to make soft material, pass through 20-mesh sieve to make granules, and dry at 60°C , take it out, sieve through a 30-mesh sieve for granulation, add appropriate amount of micropowder silica gel and magnesium stearate, mix well, press into tablets, and make 1000 pieces, to obtain.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses prevention of myocardial energy metabolism disorder, myocardial mechanism damage, cardiac function disorder and heart perfusion amount caused by ischemia and ischemia reperfusion by utilization of Astragaloside (As-IV), one of main components of qishenyiqi drop pills. The main mechanism is that Astragaloside keeps the rates of ATP/ADP and ATP/AMP through inhibition of decrease of expression levels of amyocardium ATP5D protein and an mRNA caused by ischemia and ischemia reperfusion, myocardial fiber damage and myocardium cell apoptosis are inhibited, and further myocardial infarction caused by ischemia reperfusion is decreased.

Description

technical field [0001] The invention relates to the application of a medicine, in particular to the protective effect of astragaloside IV on the heart. Background technique [0002] Astragaloside (As-IV) is a component of the traditional Chinese medicine Astragalus. Studies have shown that it is a new type of antioxidant drug, which inhibits the production of reactive oxygen species (ROS) and Bax-mediated apoptosis. The pathway works, and the relevant pharmacological effects are reported as follows: [0003] The main active ingredients in astragalus polysaccharides are polysaccharides and astragalosides. Astragalosides are divided into astragaloside Ⅰ, astragaloside Ⅱ, and astragaloside Ⅳ, among which the best biological activity is astragaloside IV, that is, astragaloside IV. Astragaloside IV not only has the effect of astragalus polysaccharide, but also some effects that cannot be compared with astragalus polysaccharide? Its medicinal effect is more than twice that of co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P9/00A61P9/10
Inventor 韩晶岩
Owner TIANJIN TASLY PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap